Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 1/2 4Phase 1 3Phase EARLY_PHASE1 1Phase 4 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 2Ovarian Neoplasms 1Gastroesophageal Cancer 1Fallopian Tube Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × relatlimab × Clear all
NCT07281924 2026-05-29

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

University of Wisconsin, Madison

Phase 1/2 Recruiting
15 enrolled
Dermatologic

Melanoma

NCT03610711 2026-05-06

REACTION

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Active not recruiting
21 enrolled
Gastrointestinal

Gastroesophageal Cancer

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Herlev Hospital

Phase 1/2 Terminated
6 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06683755 2024-11-12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡